A randomized comparaTive study Of rosuvastatin/ezetimibe 20/10mg and atorvastatin/ezetimibe 40/10mg in patients with coronary artery drug eLuting stEnt implantation Requiring high-dose stAtin/ezetimibe combiNaTion therapy: TOLERANT Trial

Not Applicable

Conditions: Diseases of the circulatory system

Registration Number: KCT0008362

Lead Sponsor: Yonsei University Yongin Severance Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

1. 19 years of age or older
2. Patients who underwent a new generation of drug elution stent implantation for cardiovascular disease

Exclusion Criteria

1. LDL cholesterol levels below 55 mg/dL without statin treatment
2. Serum AST/ALT with an acute liver disease within a month or a normal upper limit that is not continuously explained
3. Allergies or overreactions to statins
4. Estimated Dawn of Less than 1 Year
5. If it is determined that follow-up is not possible for more than one year
6. Pregnancy

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of statins changed to discontinuation or intolerance (muscle pain, muscle efficiency, elevated liver level, etc.) within a year;Rate at which LDL cholesterol remains below 55 mg/dL in all 1-year blood tests

Secondary Outcome Measures

Name	Time	Method
The rate at which LDL cholesterol is maintained at 55 mg/dL in the blood test after a month;Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary artery re-perfusion;Each secondary evaluation variable;Newly developed diabetes, difficulty in controlling sugar,;occurrence of statin-related muscle symptoms requiring therapeutic or dose changes;Increased muscle enzyme aberration (CPK > 4 x normal upper limit);Elevated liver enzyme levels (AST, ALT, or both = 3 x normal upper bound);Elevated serum creatine levels (from >50% baseline);Major bleeding (BARC type 2, 3, or 5);Reason for discontinuation or intolerance